Compare · GILD vs UPTD
GILD vs UPTD
Side-by-side comparison of Gilead Sciences Inc. (GILD) and TradeUP Acquisition Corp. (UPTD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and UPTD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.88B, about 2789.7x UPTD ($58.0M).
- GILD has hit the wire 8 times in the past 4 weeks while UPTD has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for UPTD).
- Company
- Gilead Sciences Inc.
- TradeUP Acquisition Corp.
- Price
- $130.38-2.48%
- $9.51-11.66%
- Market cap
- $161.88B
- $58.0M
- 1M return
- -5.67%
- -
- 1Y return
- +22.62%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
- Gilead Extends Tender Offer to Acquire Arcellx
- SEC Form 4 filed by O'Day Daniel Patrick
Latest UPTD
- SEC Form 10-Q filed by TradeUP Acquisition Corp.
- SEC Form 424B3 filed by TradeUP Acquisition Corp.
- TradeUP Acquisition Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- TradeUP Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form EFFECT filed by TradeUP Acquisition Corp.
- SEC Form 424B3 filed by TradeUP Acquisition Corp.
- SEC Form S-1/A filed by TradeUP Acquisition Corp. (Amendment)
- SEC Form 10-Q filed by TradeUP Acquisition Corp.
- SEC Form NT 10-Q filed by TradeUP Acquisition Corp.
- SEC Form S-1/A filed by TradeUP Acquisition Corp. (Amendment)